Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 8,064 Shares of Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total transaction of $28,224.00. Following the sale, the insider now directly owns 1,255,730 shares of the company’s stock, valued at approximately $4,395,055. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total transaction of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total transaction of $171,850.99.

Genelux Trading Down 0.9 %

Genelux stock opened at $3.45 on Thursday. The stock has a 50 day moving average of $5.86 and a 200-day moving average of $10.95. Genelux Co. has a 52 week low of $3.26 and a 52 week high of $40.98.

Genelux (NASDAQ:GNLX) last released its earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04). On average, analysts forecast that Genelux Co. will post -0.81 earnings per share for the current year.

Hedge Funds Weigh In On Genelux

Institutional investors and hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of Genelux by 250.8% during the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after buying an additional 770 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Genelux by 216.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock worth $41,000 after purchasing an additional 2,021 shares during the last quarter. Barclays PLC lifted its stake in Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after purchasing an additional 2,835 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Genelux by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after purchasing an additional 966 shares during the last quarter. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on GNLX. HC Wainwright lowered their price objective on shares of Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Benchmark reaffirmed a “speculative buy” rating and issued a $30.00 price objective on shares of Genelux in a research report on Wednesday, April 3rd.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.